Newsletters

[Biochemical Pharmacology] The authors sought to define the role of NAT10 and even the N4-acetylcytidine (ac4C) modification mediated by it in AML chemoresistance.

[Biochemical Pharmacology] The expression of LILRB3 and LILRB4 was analyzed in monocytic AML patient samples, leukemic stem cell-enriched populations, and AML cell lines, revealing frequent co-expression.

[Stem Cell Reports] Scientists investigated whether C-C Motif Chemokine Ligand 5 (CCL5) influences this process in murine and human iPSC-derived bone marrow organoid models.

[British Journal of Haematology] Researchers uncovered the potential involvement of ribonucleic acid helicase DEAH-box helicase 15 (DHX15) in AML1-ETO9a splicing and AML progression.

[Leukemia] Investigators reported that an unappreciated RNA-binding protein, Rbm5, selectively promotes murine leukemogenesis, maintains leukemia stem cell self-renewal in vivo, and is dispensable for normal hematopoiesis.

[Leukemia] An integrated analysis revealed that G3BP2 confers venetoclax resistance and correlates with poor outcomes in AML.

[Blood] Scientists identified human TMEM187, a Golgi transmembrane protein of unknown function, as a novel negative regulator of erythropoiesis.

[Cancer Cell] Because megakaryocytes are key drivers of myeloproliferative neoplasms (MPNs), the authors investigated the extent to which menin inhibition ameliorates MPN phenotypes.

[Blood Cancer Discovery] Investigators summarize how erythropoiesis is regulated under steady-state conditions, dissect the molecular mechanisms underlying anemia in myelodysplastic syndromes, and review therapeutic approaches to overcome ineffective erythropoiesis.

[FDA] The US FDA issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β thalassemia.

[Signal Transduction and Targeted Therapy] Scientists observed that MSCs, specifically BM-MSCs, mitigated mitochondrial dysfunction during the early stages of ischemia-reperfusion injury-related acute kidney injury, leading to reduced inflammation, preventing cellular injury and recovery of renal function.

[Nature Communications] Researchers showed that mesenchymal stromal cells surface-engineered with polydopamine nanoparticles conjugated to antibodies against vascular cell adhesion molecule 1 exhibit enhanced retention, survival, and therapeutic efficacy in erectile dysfunction.